The Response Evaluation Criteria in Solid Tumors (RECIST)

Medicine and Dentistry

• Anticarcinogen 33%
• Assessment 100%
• Cancer 33%
• Cancer Therapy 33%
• Central Nervous System 33%
• Combination Therapy 66%
• Defence Mechanisms 33%
• Evaluation Study 33%
• Global Health 33%
• Immunotherapy 33%
• Malignant Neoplasm 66%
• Neoplasm 33%
• Patient with Cancer 33%
• Response Evaluation Criteria in Solid Tumors 66%
• Solid Malignant Neoplasm 33%
• Therapeutic Procedure 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 33%
• Clinical Research 66%
• Malignant Neoplasm 66%
• Neoplasm 33%
• Solid Malignant Neoplasm 33%